Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesTreatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09
Finckh A et al. – The investigators used available data to estimate the cost–effectiveness of initial treatment strategies for RA. Compared with stepped care, early DMARDs or early biologic agents seem to improve outcomes, but only DMARDs do so at a cost per year of life saved that society typically considers acceptable.
Related Articles
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
Scandinavian Journal of Rheumatology, 11/17/09
Relevance Score: 93%
Review: limited evidence that psychological therapies are of benefit for adults with chronic pain
Evidence-Based Mental Health, 10/28/09
Relevance Score: 92%
Societal cost of rheumatoid arthritis patients in the US
Current Medical Research and Opinion, 11/16/09
Relevance Score: 90%
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations
Value in Health, 11/11/09
Relevance Score: 89%
Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study
Modern Rheumatology, 10/15/09
Relevance Score: 89%
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US
Current Medical Research and Opinion, 11/20/09
Metformin associated with lower cancer mortality in type 2 diabetes (ZODIAC-16)
Diabetes Care, 11/20/09
Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin
Current Medical Research and Opinion, 11/20/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US
Current Medical Research and Opinion, 11/20/09
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
Current Medical Research and Opinion, 11/17/09
Accounting for the Development of Antibacterial Resistance in the Cost Effectiveness of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in the UK
PharmacoEconomics, 11/17/09
Sponsor
Article Search
Sponsor